Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody shows promise in shrinking MS brain lesions

NCT ID NCT04879628

Ongoing Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tests a drug called SAR441344, which blocks a protein (CD40L) involved in immune attacks. The goal is to see if it can reduce new active brain lesions in people with relapsing multiple sclerosis. About 129 adults aged 18-55 with relapsing MS are participating, and they receive either the drug or a placebo. The study is active but not recruiting, and results will help determine if larger trials are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SAR441344 (a CD40L-blocking antibody)
What this could lead to
If successful, this could lead to a new treatment option that reduces brain lesion activity in people with relapsing multiple sclerosis.
What could go wrong
This is an early Phase 2 trial with only 129 participants, so results may not confirm effectiveness or safety. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Center for Neurology and Spine- Site Number : 8400007

    Phoenix, Arizona, 85032, United States

  • Investigational Site Number : 1000001

    Sofia, 1407, Bulgaria

  • Investigational Site Number : 1000002

    Pleven, 5809, Bulgaria

  • Investigational Site Number : 1000003

    Sofia, 1113, Bulgaria

  • Investigational Site Number : 1240001

    Gatineau, Quebec, J8Y 1W2, Canada

  • Investigational Site Number : 2030001

    Jihlava, 58633, Czechia

  • Investigational Site Number : 2030002

    Hradec Králové, 50005, Czechia

  • Investigational Site Number : 2030003

    Brno, 65691, Czechia

  • Investigational Site Number : 2030004

    Teplice, 415 29, Czechia

  • Investigational Site Number : 2030005

    Ostrava - Poruba, 70852, Czechia

  • Investigational Site Number : 2500006

    Calais, 62107, France

  • Investigational Site Number : 2760004

    Münster, 48149, Germany

  • Investigational Site Number : 2760012

    Leipzig, 04103, Germany

  • Investigational Site Number : 6430001

    Moscow, 127015, Russia

  • Investigational Site Number : 6430002

    Kazan', 420032, Russia

  • Investigational Site Number : 6430003

    Saint Petersburg, 194044, Russia

  • Investigational Site Number : 6430004

    Saint Petersburg, 197110, Russia

  • Investigational Site Number : 6430005

    Saint Petersburg, 197022, Russia

  • Investigational Site Number : 6430006

    Moscow, 117997, Russia

  • Investigational Site Number : 6430007

    Moscow, 117556, Russia

  • Investigational Site Number : 6430008

    Tyumen, 625000, Russia

  • Investigational Site Number : 7240002

    Vigo, 36312, Spain

  • Investigational Site Number : 7240004

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7920001

    İzmit, 41380, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Mersin, 33070, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Istanbul, 34265, Turkey (Türkiye)

  • Investigational Site Number : 7920004

    Eskişehir, 26040, Turkey (Türkiye)

  • Investigational Site Number : 8040002

    Kyiv, 01135, Ukraine

  • Investigational Site Number : 8040003

    Odesa, 65025, Ukraine

  • Investigational Site Number : 8040004

    Lviv, 79013, Ukraine

  • Investigational Site Number : 8040005

    Vinnytsia, 21001, Ukraine

  • Investigational Site Number : 8040006

    Dnipro, 49089, Ukraine

  • Investigational Site Number : 8040008

    Ivano-Frankivsk, 76493, Ukraine

  • Investigational Site Number : 8040010

    Dnipro, 49005, Ukraine

  • Medical College of Wisconsin- Site Number : 8400006

    Milwaukee, Wisconsin, 53226, United States

  • The Neurological Institute Site Number : 8400004

    Charlotte, North Carolina, 28204, United States

  • University of South Florida Site Number : 8400001

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.